20 results
20-F/A
2020 FY
SLN
Silence Therapeutics Plc
29 Apr 21
Annual report (foreign) (amended)
4:26pm
to a target after we have commenced a Phase 1 trial of a product candidate directed to that target, then we would have the right to either complete or wind
424B4
SLN
Silence Therapeutics Plc
12 Apr 21
Prospectus supplement with pricing info
11:12am
complete or wind down the Phase 1 trial, and Mallinckrodt would be responsible for our costs incurred through the date of termination.
AstraZeneca
424B4
pz4nn3vmp5gt8 ps0
12 Apr 21
Prospectus supplement with pricing info
11:11am
POS AM
xvb1xl
8 Apr 21
Prospectus update (post-effective amendment)
9:31am
POS AM
u6z 8ht07
8 Apr 21
Prospectus update (post-effective amendment)
9:18am
20-F
9r0syar en4173
30 Mar 21
Annual report (foreign)
5:22pm
424B7
0leagv1j9a9dfn4v8i
15 Mar 21
Prospectus with selling stockholder info
10:07am
F-1/A
ydwdd 5me1
11 Mar 21
Registration statement (foreign) (amended)
4:02pm
F-1
satjr8k ml6k1axt
8 Mar 21
Registration statement (foreign)
9:50pm
POS AM
newlgvyljwzn
23 Sep 20
Prospectus update (post-effective amendment)
4:47pm
424B4
vrf0ftbhgs 5rx9eh
8 Sep 20
Prospectus supplement with pricing info
7:31am
F-1
9aq51y r3c
20 Aug 20
Registration statement (foreign)
4:50pm
F-1
EX-10.5
1kjchqy 5uwxu
20 Aug 20
Registration statement (foreign)
4:50pm
F-1
EX-10.6
nkorpbf8
20 Aug 20
Registration statement (foreign)
4:50pm
DRS/A
10aprqe l4j
31 Jul 20
Draft registration statement (amended)
12:00am
DRS
EX-10
f0vuip498ujr3
22 Jun 20
Draft registration statement
12:00am
DRS
EX-10
emtxn
22 Jun 20
Draft registration statement
12:00am
- Prev
- 1
- Next